The total yield of gemcitabine was 15.8%.
结果：合成了盐酸吉西他滨，总收率15.8%。
Patients could not have had prior chemotherapy with gemcitabine or cisplatin.
同时，这些患者既往不能有包含吉西他滨或者顺铂的化疗史。
OBJECTIVE: To review the pharmacology and clinical application of gemcitabine.
目的：综述双氟去氧胞苷的药理及临床应用。
Objective: To synthesize of gemcitabine hydrochloride and optimize the process.
目的：合成抗癌药物盐酸吉西他滨并改进合成工艺。
Objective To study the antitumor effect of gemcitabine in chemotherapy with breast cancer.
目的探讨吉西他滨在乳腺癌化疗中的作用。
After treatment with gemcitabine and CD40 antibody, the tumors shrank in 30% of the animals.
采用吉西他滨和CD 40抗体治疗后，30%的小鼠肿瘤瘤体缩小。
Gemcitabine is a new active drug in the treatment of advanced non small cell lung cancer (NSCLC).
吉西他滨是近年来治疗晚期非小细胞肺癌的有效新药。
A combination of gemcitabine and capecitabine is sometimes used to treat metastatic renal cell cancer.
吉西他滨和卡培他滨的组合有时用来治疗转移性肾细胞癌。
Gemcitabine (iv over 30 minutes) is the standard therapy for inoperable pancreatic cancer of advanced stage.
吉西他滨30分钟静脉滴注是晚期胰腺癌的标准治疗方案。
Objective To observe the results of gemcitabine combined with capecitabine on anthracycline-resistant breast cancer.
目的观察吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效与毒性反应。
Results In primary breast cancer, the antitumor effect of taxane is better than anthracycline and gemcitabine(P <0.01).
对复发性乳腺癌患者，吉西他滨的疗效则明显优于蒽环类和紫杉类药物（P<0。01）。
Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine.
厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。
Eligible patients were randomized to either treatment with gemcitabine alone (204 participants) or in combination with cisplatin (206).
这些满足适应症的患者被随机分至单用吉西他滨组(204例)和顺铂-吉西他滨联用组(206例)。
Conclusion The treatment of gemcitabine combined cisplatin peritoneal perfusion had curative effect on primary hepatocellular carcinoma.
结论健择联合腹腔灌注顺铂对原发性肝细胞癌有明显的治疗效果。
ObjectiveTo evaluate the efficacy, clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.
目的观察吉西他滨联合厄洛替尼方案治疗进展期胰腺癌的疗效、临床获益反应和毒性反应。
Conclusion: Neoadjuvant chemotherapy with gemcitabine and cisplatin is well tolerated and does not impair resectability of pancreatic cancer.
结论：吉西他滨联合顺铂的新辅助化疗耐受性好，并且没有破坏胰腺癌的可手术性。
Objective to observe the efficacy and toxicity of gemcitabine plus Carboplatin in the treatment of advanced non-small-cell lung cancer (NSCLC).
目的观察吉西他滨联合伯尔定治疗晚期非小细胞肺癌的疗效及毒副作用。
Objective to study the effects of the low-dose gemcitabine sensitizing radiotherapy to the Pancreatic cancer as well as its toxic side effects.
目的探讨低剂量健择增敏放射治疗胰腺癌的疗效及毒副反应。
To explore the significance of implanted 125i radioactive particles into tumor combined with gemcitabine to treat extended local pancreas cancer.
目的探讨放射性125I粒子植入联合吉西他滨治疗进展期胰腺癌的临床价值。
Purpose: To evaluate the effect of postoperative after-loading radiotherapy with the use of gemcitabine in 22 patients with primary liver cancer.
目的：探讨术后后装放疗加吉西他滨全身化疗对原发性肝癌的治疗效果。
Objective To observe the efficiency for patients of intermediate and advanced pancreatic cancer treated by body gamma knife combined Gemcitabine.
目的观察体部伽玛刀联合健择治疗中晚期胰腺癌的近期疗效。
Objective To observe the detoxification of Shenfu Injection(SHF) on Gemcitabine plus Cisplatin(GP) for treating non-small cell lung cancer(NSCLC).
目的观察参附注射液对健择联合顺铂方案（GP）治疗非小细胞肺癌的减毒作用。
Median survival for patients treated with fluorouracil plus folinic acid was 23.0 months and for patients treated with gemcitabine was 23.6 months.
接受氟尿嘧啶联合亚叶酸方案治疗或是吉西他滨方案治疗患者的中位生存期分别为23.0个月及23.6个月。
Objective: to evaluate the clinical effect and toxicity of gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer (NSCLC).
目的观察了解吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒性反应。
The drug most commonly used to treat pancreatic cancer is called gemcitabine and works by entering into the DNA of cancer cells and stopping replication.
Govindarajan解释说，目前最常见的胰腺癌治疗药物是吉西他滨，这个药物通过进入肿瘤细胞DNA并抑制DNA复制来发挥抗癌作用。
Objective To compare the efficacy and side effects between 3-week and 4-week schedule of gemcitabine plus cisplatin for advanced non-small cell lung cancer.
目的比较健择联合顺铂治疗晚期非小细胞肺癌3周和4周方案的疗效和不良反应。
Conclusion the toxic reactions of single application of gemcitabine is mild, which improve the safety of medication and the quality of life in aged patients.
结论单药健择不良反应轻，能有效提高老年病人生存质量及用药安全性。
Objective: To evaluate the curative effect, safety and adverse reaction of domestic and imported gemcitabine hydrochloride in non-small cell lung cancer (NSCLC).
目的：评价国产药与进口药盐酸吉西他滨治疗非小细胞肺癌(NSCLC)的疗效、安全性及不良反应。
Treatment with bevacizumab plus gemcitabine-erlotinib was well tolerated: safety data did not differ from previously described safety profiles for individual drugs.
吉西他滨-厄洛替尼联合贝伐单抗治疗有很好的耐受性：得到的安全数据和先前描述的个性化药物治疗得到的安全数据不同。
Treatment with bevacizumab plus gemcitabine-erlotinib was well tolerated: safety data did not differ from previously described safety profiles for individual drugs.
吉西他滨-厄洛替尼联合贝伐单抗治疗有很好的耐受性：得到的安全数据和先前描述的个性化药物治疗得到的安全数据不同。
应用推荐